OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
Apr 10, 2023 • 22min
S8 Ep35: Gynecologic Cancer Experts Review 2023 SGO Research and Treatment Updates
Presenters from the 2023 SGO Annual Meeting share their insights on the treatment of patients with gynecologic cancers.
Apr 6, 2023 • 27min
S8 Ep34: Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management
Drs Mercado and Kovacs discuss the importance of multidisciplinary approaches to lung cancer screening and management, barriers to lung cancer screening that affect how early certain patients are diagnosed with this disease, and where the future of lung cancer detection and treatment is headed.
Apr 3, 2023 • 17min
S8 Ep33: Kishan Discusses GI Toxicity Reduction With MRI-Guided SBRT in Prostate Cancer
Dr Kishan discusses the use of MRI-guided SBRT in prostate cancer to reduce acute genitourinary and gastrointestinal toxicity; findings from the MIRAGE study; and how MRI-guided SBRT allows for tighter planning margins, thereby reducing both physician-reported and patient-reported bowel and bladder toxicities.
Mar 30, 2023 • 10min
S8 Ep32: FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer
Dr Bidard discusses the FDA approval of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, key efficacy and safety data from the EMERALD trial, and the importance of testing for ESR1 mutations in patients with ER-positive, HER2-negative disease.
Mar 27, 2023 • 43min
S8 Ep31: Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration
Faculty from the 40th Annual Miami Breast Cancer Conference® feature updates in the treatment of patients across the breast cancer continuum.
Mar 20, 2023 • 8min
S8 Ep29: FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer
Dr Tolaney discusses the FDA approval of sacituzumab govitecan in patients with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer; key data from the TROPiCS-02 trial; and how this agent can fulfill unmet needs for this patient population.
Mar 16, 2023 • 14min
S8 Ep28: Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC
Dr Raez discusses findings from a study of patients with newly diagnosed non–small cell lung cancer who received both liquid and tissue biopsy, the benefits of liquid biopsy’s relatively short turnaround time, and financial barriers to conducting multiple next-generation sequencing tests per patient.
Mar 13, 2023 • 16min
S8 Ep27: Milner, Dalal, and Ligon Discuss Stem Cell Transplant Methods, Results, and Risk Factors in Pediatric Patients
Drs Milner, Dalal, and Ligon discuss hematopoietic stem cell transplant in children with severe aplastic anemia, graft failure risk factors in children receiving hematopoietic cell transplant for non-malignant disorders, and the use of mediports for CAR T-cell infusion.
Mar 9, 2023 • 9min
S8 Ep26: FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC
Dr Herbst discusses the FDA approval of adjuvant pembrolizumab in non–small cell lung cancer, key efficacy and safety data from the KEYNOTE-091 trial, and future research efforts that may further improve outcomes in this population.
Mar 6, 2023 • 28min
S8 Ep25: CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice
Drs Khushalani, Dietrich, Luke, and Patel discuss the nuances of defining resectability in cutaneous squamous cell carcinoma, the evolving treatment paradigm of resectable disease, and how to translate updated data with cemiplimab into clinical practice.
